OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer. To…
Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.
E. Gabriela Chiorean, MD, FASCO, highlights the significance of encorafenib plus cetuximab and mFOLFOX6’s FDA approval in BRAF V600E-mutated metastatic CRC.
The EORTC offers a one-year research fellowship (renewable to a maximum of 3 years) to learn the methodology of cancer clinical studies and gain first experience working…
A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.
Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.
Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.
Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.
Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.